福辛普利辅助治疗老年冠状动脉粥样硬化性心脏病并发心力衰竭患者的效果

Efficacy of fosinopril in the treatment of elderly patients with combined coronary atherosclerotic heart disease and heart failure

目的探讨福辛普利辅助治疗老年冠状动脉粥样硬化性心脏病并发心力衰竭(CHD-HF)患者的效果。方法选择2020年8月至2022年8月呼伦贝尔市人民医院老年病科收治的120例老年CHD-HF患者为研究对象,其中男63例(52.50%),女57例(47.50%),按照随机数表法分为对照组和观察组。对照组(n=60)给予普伐他汀治疗,观察组(n=60)在对照组基础上给予福辛普利辅助治疗,观察两组临床疗效、心功能、血管内皮功能、不良反应。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗后,观察组左心室射血分数(LVEF)、左心室短轴缩短率(LVFS)水平高于对照组,差异有统计学意义(P<0.05);观察组左心室收缩末期内径(LVESD)低于对照组,差异有统计学意义(P<0.05);观察组血管内皮生长因子(VEGF)、内皮素-1(ET-1)水平低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论福辛普利辅助治疗老年CHD-HF可以提高临床疗效和心功能,改善血管内皮功能,且不良反应增加不明显。

Objective To explore the efficacy of fosinopril in the treatment of elderly patients with combined coronary atherosclerotic heart disease and heart failure(CHD-HF).Methods A total of 120 elderly CHD-HF patients admitted to the Department of Geriatrics of Hulunbuir People’s Hospital from August 2020 to August 2022 were selected as the study subjects,including 63 males(52.50%)and 57 females(47.50%),who were divided into a control group and an observation group using a random number table method.The control group(n=60)was treated with pravastatin according to the routine therapy,and the observation group(n=60)was treated with fosinopril based on the therapy of the control group.The clinical efficacy,cardiac function,vascular endothelial function,and adverse reactions of the two groups were observed.Results The total effective rate of the observation group was higher than that of the control group,with statistically significant difference(P<0.05).After treatment,the levels of left ventricular ejection fraction(LVEF)and left ventricular short axis shortening rate(LVFS)in the observation group were higher than those in the control group,with statistically significant differences(P<0.05).The left ventricular end-systolic diameter(LVESD)of the observation group was shorter than that of the control group,with statistically significant difference(P<0.05).The levels of vascular endothelial growth factor(VEGF)and endothelin-1(ET-1)in the observation group were lower than those in the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Fosinopril as an adjuvant therapy for elderly patients with CHD-HF can improve clinical efficacy and cardiac function as well as vascular endothelial function,and it has no significant effect on the increase in adverse reactions.